Abstract miRNA regulate gene expression at post-transcriptional level and fine-tune the key biological processes, including cancer progression. Here, we demonstrate the involvement of miR-200b in the metastatic spread of prostate cancer. We identified miR-200b as a downstream target of androgen receptor and linked its expression to decreased tumorigenicity and metastatic capacity of the prostate cancer cells. Overexpression of miR-200b in PC-3 cells significantly inhibited their proliferation and the formation of subcutaneous tumors. Moreover, in an orthotopic model, miR-200b blocked spontaneous metastasis and angiogenesis by PC-3 cells. This decreased metastatic potential was likely due to the reversal of the epithelial-to-mesenchymal transition, as was evidenced by increased pan-epithelial marker E-cadherin and specific markers of prostate epithelium, cytokeratins 8 and 18. In contrast, mesenchymal markers, fibronectin and vimentin, were significantly downregulated by miR-200b. Our results suggest an important role for miR-200b in prostate cancer progression and indicate its potential utility for prostate cancer therapy.
Introduction
MicroRNA (miRNA) are short, (21-22 nucleotides) non-coding RNA that bind to mRNA and repress gene expression by mRNA degradation/destabilization or through impaired translation [1] . MicroRNA are first transcribed as 100 bp primary miRNA hairpin structures, which are subsequently cleaved by Drosha into pre-miRNA and exported from the nucleus into the cytoplasm for further processing [2, 3] . Cleavage of pre-miRNA by Dicer proteins yields 22 bp double-stranded molecules, of which one strand is selectively loaded onto the Argonaute proteins, which facilitate miRNA binding to the 39UTR target sequences on mRNA. MiRNA play pivotal roles in multiple developmental and pathological processes, including cancer of the breast, skin, lung, and cervix [4] [5] [6] [7] [8] [9] .
The miRNA hsa-miR-200b belongs to a family that includes miR-200a, miR-200c, miR-141, and miR-429. Dysregulation of mir-200b has been ascribed a critical role in the epithelial to mesenchymal transition (EMT) and metastasis in cancers such as breast, gastric, and pancreatic carcinomas [10] [11] [12] . Human miR200b participates in a double feedback loop with the two transcriptional regulators of E-Cadherin, ZEB1 and ZEB2 [13] . In normal epithelial cells, miR-200b is expressed at high levels; by targeting the 39UTR regions of pro-metastatic transcriptional factors ZEB1 and ZEB2 it blocks the expression and halts EMT [10] . In contrast, in mesenchymal cells, where ZEB1/ZEB2 expression is abnormally high, they suppress the miRNA of miR-200 family by blocking their promoter activity [13] . Multiple studies assess miR-200b function in EMT, although there are few attempts to address its role in the primary tumor growth.
Here, we demonstrate that miR-200b possesses a similar activity in prostate cancer. Seeking to identify miRNA that contribute to decreased aggressiveness and tumorigenesis in prostate cancer, we performed miRNA profiling of cell lines with inducible expression of androgen receptor previously developed in our lab. We found that miR-200b was significantly upregulated in the poorly tumorigenic PC3 AR-positive cells and that overexpression of miR-200b led to decreased tumor growth. This decreased tumorigenesis was likely due to decreased proliferation. On the other hand, miR-200b strongly upregulated the epithelial cell marker E-cadherin in PCa cells, while the mesenchymal markers Fibronectin and Vimentin were concomitantly decreased. In agreement with the analyses performed in other tumor types, ZEB1, a transcriptional regulator of E-Cadherin was also decreased upon miR-200b overexpression. In addition, miR200b reduced the invasive potential of the PCa cells in vitro and decreased metastasis. Our results show that miR-200b decreases tumor growth and reverses EMT in prostate cancer.
Methods

Animal Welfare Assurances
All studies involving laboratory animals (mice) were approved by Northwestern University Animal Care and Use Committee and performed in agreement with the guidelines adopted and suggested by the National Institutes of Health (Animal assurance number A3283-01, expiration date 5/31/2014).
Cell Lines and Treatment Conditions
PC3 cells transfected with inducible wild-type androgen receptor (AR) or control plasmid were established previously [14] . Cells were maintained in RPMI medium supplemented with 10% Tetracycline-free Fetal Bovine Serum (FBS), 2% penicillin/ streptomycin, 50 mg/ml Zeocin and 1 mg/ml Blasticidin. For AR expression, PC3-AR cells were treated for 5 days with 1 mg/ml of Doxycycline and 1 nM of methyltrienolone (R1881) in phenol red free RPMI media supplemented with 10% Charcoal-Stripped FBS, 2% penicillin/streptomycin, 50 mg/ml Zeocin and 1 mg/ml Blasticidin. The parental PC3 cells were maintained in RPMI with 10% FBS and 2% penicillin/streptomycin. All cells were grown at 37uC and 5% CO 2, in a humidified incubator.
Immunoblotting
Cells were plated at a density of 100,000 cells per 10 cm dish. The cells were collected by scraping in phosphate buffered saline (PBS) and centrifuged at 2,500 RPM for 10 minutes at 4uC. The cell pellet was lysed in Ripa buffer (Sigma, St. Louis, MO) supplemented with 1X protease/phosphatase inhibitor solution (Thermo Scientific, Waltham, MA) and centrifuged at 12,000 RPM for 20 minutes at 4uC. The concentration of the supernatant was determined in triplicate by protein assay (DC Protein Assay, Biorad, Hercules, CA). The lysates were electrophoresed on 4%-20% Tris HCL polyacrylamide gels (Biorad, Hercules, CA). Protein lysate was transferred overnight onto PVDF membranes (GE Healthcare Life Sciences, Pittsburg, PA). Each membrane was rinsed in 1X Tris-buffered saline with 0.1% Tween 20 (TBS-T), blocked with 5% non-fat milk in TBS-T and probed with antibodies as indicated in Table S3 .
RNA Extraction
For miRNA detection, total RNA was isolated with miRNeasy Mini kit (Qiagen, Valencia, CA). For mRNA extraction, tumors were snap-frozen in liquid nitrogen and transferred into RNA stabilization solution (Ambion, Life Technologies, Grand Island, NY). The tumors were maintained at 280uC and RNA extraction was performed using miRNeasy Mini kit (Qiagen, Valencia, CA). The RNA concentration and purity was measured with NanoVue Plus spectrophotometer (GE Healthcare Life Sciences, Pittsburg, PA).
Real Time RT-PCR
RNA was reverse transcribed with miScript II RT Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. The resulting cDNA was used for real-time PCR analysis using miScript SYBR Green PCR kit (Qiagen, Valencia, CA). For individual miRNA quantification we used miScript Primer Assays (Qiagen, Valencia, CA). For polymerase chain reaction (PCR) analysis, forward and reverse primers were designed and purchased from Integrated DNA Technologies (Coralville, IA) and reactions performed using SYBR Green super mix (Quanta Biosciences, Gaithersburg, MD). The reactions were performed in a Thermal iCycler (Biorad, Hercules, CA). Each sample was tested in triplicate.
miRNA Array Analysis PC3-AR cells were treated with Doxycycline (Dox) and R1881 (as described above) for expression and activation of Androgen Receptor (AR), respectively. RNA was extracted as described above and 5 mg of each sample was sent to LC Sciences (Houston, TX) for array analysis. Samples were labeled with Cy 3 or Cy 5 and the intensity ratio of each was used to determine the changes in miRNA expression level. A 20-nucleotide RNA control sequence complementary to multiple control probes spotted on each chip was included in each sample as an internal control. The microarrays were performed in triplicate for human, mouse and rat sequences. The potential target spectrum for select miRNA was defined using Sanger miRBase 11.0. Statistical significance was determined using Student's T-test for p,0.10, p,0.05 and p,0.01.
miR-200b Overexpression
Shuttle vector encoding precursor sequence hsa-miR-200b (pMIRNA1 pCDH-CMV-MCS-EF1-copRFP) and control vector (pCDH-CMV-MCS-EF1-copRFP) from System Biosciences (SBI, Mountain View, CA) were propagated in Luria Broth +50 mg/ml ampicillin overnight at 30uC in an orbital shaker. Endotoxin-free plasmid DNA was isolated using Endo-Free Maxi Prep kit (Qiagen, Valencia, CA). Lentiviral particles were produced for each plasmid in HEK293T cells using the pMD2.G envelope and psPAX2 2 nd generation packaging plasmids (AddGene, Cambridge, MA). The titer was determined by flow cytometry of infected cells as described previously [15] . For transfection, PC3 cells were seeded in 6-well plates at 10 5 cells/well. The following day, the media was replaced with 1 ml of 1X DMEM containing 
Tumorigenesis Assays
(1) Subcutaneous inoculation. Parental PC3 cells, PC3 cells transduced with control lentivirus and miR-200b cells were grown as described above, harvested and resuspended at 2610 7 cells/ml in serum-free RPMI. One hundred mL of cell suspension (2610 6 cells/mouse) were injected subcutaneously into the rear hindquarters of athymic male mice (Nu/Nu, n = 5). The tumors were measured with microcalipers three times a week and the experiment was terminated at 29 days post implantation. The tumors were snap-frozen in liquid nitrogen and stored at 280uC for subsequent analysis.
(2) Orthotopic implantation of tumor cells was performed as described previously [16] . Briefly, midline incisions were made, superior to the genital area of supine anesthetized male athymic mice (nu/nu). The bladder was externalized and extended with a cotton swab to reveal the seminal vesicles and the dorsum of the prostate. Tumor cells in 50 ml of serum-free RPMI (10 6 per animal) were injected into the prostate and the muscle and skin were closed with sutures and metal clips, respectively. All procedures were performed in sterile environment. Metal clips were removed 2 weeks post-injection. Tumor growth was monitored by GFP fluorescence, using small animal imaging system OV100 (Olympus). The experiment was terminated 20 days post implantation. The tumors were excised and snapfrozen for subsequent analysis. To assess metastasis, the residual fluorescence was measured after removal of the primary tumor.
Proliferation Assay
The cells were seeded in triplicate in 96 well plates at 3610 3 cells/well. After 24, 48, and 72 hours, 10 ml of WST-1 reagent (Roche, Indianapolis, IN) was added to each well and incubated for 2 hours. The absorbance was measured for each time point at 450 nm wave length using the Biorad microplate reader (Biorad, Hercules, CA).
In Vitro Invasion Assay
Transwell inserts (Corning, Tewksbury, MA) were coated with 100 ml of 1 mg/ml of Phenol Red free Growth Factor Reduced Matrigel (BD Biosciences, Franklin Lakes, NJ) and allowed to solidify at 37uC in a tissue culture incubator for 24 hours. The cells were resuspended at a density of 10 6 cells/200 ml in serum-free RPMI, seeded in duplicates in the top part of the coated inserts and incubated at 37uC for 24 hours, with 700 ml of 10% FBS added to the lower chamber as a chemoattractant. The cells were fixed and stained using DiffQuick Fixative solutions (Dade Behring, Malvern, PA) and 6 fields were imaged for each experimental condition. The invasion was calculated as percent invaded cells. The experiment was performed twice.
Cell Cycle Analysis
The cells were seeded at 10 6 cells/ml in RPMI supplemented with 0.2% FBS. After 48 hrs the cells were trypsinized, washed twice in cold PBS, fixed in 10 ml 75% ice-cold ethanol and kept overnight at 220uC. The cells were washed twice in 1X PBS at 4uC, resuspended in 2.0 ml DAPI staining solution (0.1% TritonX 100 in 10 ml PBS, 100 ml of 1 mg/ml DAPI) and analyzed by FACS.
Statistical Analysis
All quantitative data were generated from at least two independent experiments pooled together, with each individual data point performed in triplicates. Standard Deviation (SD) were calculated using Microsoft Excel software. To determine statistical significance of the observed difffrences, we have performed pairwise comparison of the datasets, using one-tailed Student's T-test. Statistical significance was set at P value not exceeding 0.05.
Results
miR-200b is Upregulated by AR
Previous data from our group showed that androgen receptor (AR) inhibits tumorigenic properties of the AR-negative prostate cancer cell line, PC-3 [14] . MicroRNA are important modifiers of biological functions, including tumor growth. We sought the miRNA that are controlled by AR and involved in the negative regulation of prostate cancer progression. For this purpose, we performed miRNA profiling of the previously generated cell line with tetracycline-inducible AR expression ( [14] , Fig. 1a ). The cells were treated with Doxycycline (Dox) to ensure AR expression and with R1881, to induce AR nuclear translocation and transcriptional activity. Microarray analysis revealed statistically significant differential expression of 837 individual miRNA in response to AR activation (p,0.05 as determined by Students' T-test), of which 116 were showed P-values below 0.01 (Figure 1b , Tables S1 and S2). We selected miRNA that were changed more than 2-fold and analyzed their potential targets and functions using Sanger miRBase version 11.0 and Diana Micro T version 3.0. Eight miRNA were selected based on their potential involvement in cancer progression as was determined by in silico analysis and published studies. Five of the selected miRNA upregulated in the less tumorigenic PC3-AR cells were also associated with decreased tumorigenesis in other cancers (Table 1) . MicroRNA from the miR-200 cluster (miR-200a, miR200b) have been shown to act as tumor suppressors in gastric, cervical, lung, breast and prostate cancers [9, 10, 17, 18] . Increased miR-200c levels have been linked to decreased metastasis in melanoma, squamous cell carcinoma, and prostate cancer [6, 18, 19] . miR-30a and miR 30-d expression is significantly decreased in chronic myeloid leukemia, non-small cell lung cancer, renal cell carcinoma, and prostate cancer [20] [21] [22] [23] . In contrast, miR-7 and miR-9 levels were decreased in the less tumorigenic cell line. In accord, miR-7 has been identified as an oncogene in renal cell carcinoma [24] and miR-9 ascribed a role in leukemogenesis [25] [26] [27] . Low miR-196a levels were observed in malignant melanoma [28] (Table 2) .
We have validated select microRNA identified by array analysis using real-time PCR. Indeed, miR-200b, 30a, and 30d were increased, and miR-9 decreased, and these changes were statistically significant (p#0.05) (Figure 2a) . We selected miR200b for further analysis since it showed the highest fold change and because of its known role in EMT and metastasis [10, 13] .
We measured miR-200b levels in PC3-AR cells treated with the combination of Doxycycline, a synthetic androgen R1881 and the anti-androgen flutamide, a competitive inhibitor of AR function. MiR-200b was significantly increased in response to R1881 and this increase was abolished by flutamide in a dose dependent manner, suggesting a direct transcriptional regulation by AR (Figure 2b ).
miR-200b Suppresses the Growth of Prostate Cancer Xenografts
We next sought the effect of miR-200b expression on prostate cancer tumorigenesis. We overexpressed miR-200b in PC3 cells by transduction with high-titer lentivirus, using empty vector (pCDH-CMV-MCS-EF1-copRFP) as a negative control, and confirmed miR-200b expression by real-time RT-PCR (Figure 3a) . The resultant cell lines and parental PC3 cells were subcutaneously injected into male athymic nude mice. Importantly, tumors formed by the cells expressing miR-200b were significantly smaller then the tumors formed by the parental PC3 and the cells transduced with control vector (Figure 3b) . Importantly, miR-200b expression was maintained for the duration of the experiment, as was verified by real-time RT-PCR (Figure 3c ). Because tumor interactions with its microenvironment play a critical role in tumor progression, we performed orthotopic implantation of the PC3-200b and control cell lines as previously described [16] into the dorsal prostate of male athymic mice. We took advantage of the RFP marker incorporated in the bicistronic lentiviral vector to perform longitudinal in vivo imaging. The overall fluorescence predissection was significantly lower in mice bearing PC3 miR-200b positive tumors compared to the vector control group (Figure 3d 
miR-200b Suppresses Proliferation of the PCa Cells
miR-200b Reverses Epithelial to Mesencymal Transition in PCa Cells
In previous studies, miR-200b expression in breast, gastric, and renal cell carcinoma correlates with the more differentiated state, and re-introduction of miR-200b reverses EMT [10, 11, 29] . These changes can ultimately contribute both to decreased tumor growth and metastasis. Therefore, we analyzed the levels of known EMT and differentiation markers expressed by the PC-3 cells in the presence or absence of miR-200b. First, Western blot analysis showed a significant increase in the typical differentiation markers of prostate epithelium Cytokeratin CK8 and CK18 by miR-200b, suggesting a more differentiated state of miR-200b positive cells (Figure 4) .
In agreement, the levels of E-cadherin were also increased (Figure 5a ), suggesting a shift towards epithelial phenotype. Furthermore, Vimentin, a mesenchymal marker, underwent a statistically significant decrease upon miR-200b expression. Another mesenchymal marker, fibronectin (FN) displayed a similar trend although the decrease did not reach statistical significance (Figure 5b) . Because in previous studies miR-200b controlled E-Cadherin and EMT by repression of the transcriptional factor ZEB1, we have assessed both total ZEB1 protein and RNA levels in miR-200b-positive and control PC-3 cells. We observed a 
miR-200b Decreases Invasion and Metastasis by PC-3 Cells
Because miR-200b caused EMT reversal in PCa PC-3 cells, it was reasonable to expect a decreased invasive potential as well. Using a standard procedure to measure cell invasion, we observed a significant decrease in the percentage of invaded cells due to miR-200b expression as compared to control (Figure 5e ). This decreased invasion likely underlies the decreased regional metastasis by PC3 miR-200b cells in vivo.
Orthotopic injection of parental PC-3 and vector control cells into the dorsal prostates of athymic male mice resulted in spontaneous metastasis, as was detected after the removal of the primary tumors ( Fig. 5f and Figure S2 ). The overall fluorescence due to metastasis was dramatically decreased in mice implanted with the PC-3 cells overexpressing miR-200b (Figure 5f , g and Figure S2 ). Thus our data suggest that miR-200b significantly decreases mesenchymal features in prostate cancer cells and thus reduces their invasive characteristics and metastatic potential.
miR-200b Reduces Tumor Angiogenesis
Another feature that may enable metastasis is angiogenesis and EMT is often accompanied by increased angiogenesis. The expression of miR-200b appeared to reverse angiogenic switch in PC-3 cells as was evidenced by decreased microvascular density in the miR-200b positive tumors compared to the parental PC-3 or vector control tumors (Fig. 6 ).
Discussion
The miR-200 family is a tumor-suppressive family of micro-RNA that play critical roles in suppression of EMT. While the role of miR-200 family in breast and some other epithelial cancers is well established, there are few findings linking miR-200 with prostate cancer. A small-scale study (20 patients) suggests an association between the biochemical relapse after radical prostatectomy and the lower levels of miR-200c [30] . One study by He et al. demonstrates that low levels of miR-200b-3p in androgenindependent cells are caused by decreased expression of the p-53-related protein p73 and contribute to increased proliferation [31] . The two clusters encoding miR-200 family are found on chromosomes 1 and 12, with miR-200b, miR-200a, and miR-429 on chromosome 1 and miR-200c and miR-141 on chromosome 12. MicroRNA 200c is thought to be epithelial-specific and its expression is repressed by hypermethylation of the proximal CpG island in the fibroblasts and in breast cancer cell lines [32] . In the PC-3, but not in LnCaP and DU145 PCa cells, similar hypermethylation of the CpG island coincides with the low levels of miR-200c and miR-141 [32] . Consistent with our results, in this study the PC3 cells negative for miR-200c and miR-141, display a clear mesenchymal phenotype and the capacity for invasion and metastasis [32] . Two studies indicate the role for miR-200 in tumorigenesis by the PCa stem cells. In stem-like PCa cells the expression of Sox2, Nanog, Oct4, Lin28B and/or Notch1 is consistent with enhanced clonogenic survival and the ability to form spheroids (prostaspheres). These stem-like features are connected to decreased expression of miR-200b/c and/or of let-7 family whereby re-expression of miR-200 inhibits prostasphere formation and reduces Notch1 and Lin28B, the drivers of self-renewal [33] . In an unrelated study, the invasive tumorigenic clones derived from the benign prostatic hyperplasia (BPH)-1 cell line chronically exposed to TGF-b display prominent EMT features with high levels of SNAI2, ZEB1, and ZEB2, all confirmed miR-200 targets; however, the basal miR-200 levels in these cells remain unaltered suggesting a divergent mechanism [34] .
The augmented stem-like features suggest enhanced tumorigenicity. Indeed, multiple groups have shown that miR-200b alters the growth rate of experimental tumors by the cultured PCa cells [35] . Our data clearly corroborate these observations. MiR-200b expression dramatically reduced the size of both subcutaneous and orthotopic tumors formed by the PC-3 cells. In contrast with previous observations in breast cancer cells and preclinical models of breast cancer, which showed dramatic reduction of proliferative capacity by miR-200 family members [36] , we found that miR-200 only modestly decelerated the growth of PC-3 cells in vitro and in vivo. It is possible that miR-200b alone is insufficient to inhibit proliferation: microRNA are generally changed in concert and multiple miRNA target a single trait. The miR-200 family has often been studied in tandem, and our array analysis also revealed lesser but significant increases in miR-200c and miR-429, which could further enhance anti-proliferative effect of miR-200b.
Our study for the first time identified miR-200b as direct target of androgen receptor: in AR-expressing PC-3 cells miR-200 levels were increased by DHT and the anti-androgen Flutamide fully abolished this increase. In PCa, hyperactivation or amplification of AR signaling often increases proliferation and contribute to tumorigenesis [37] . However, in some contexts, including PC-3 cells, AR opposes PCa progression [14, [38] [39] [40] . This tumor suppressive activity is consistent with AR role as the driver of differentiation in prostate epithelium [41] . Our results suggest that the AR may contribute to the maintenance of miR-200 family members in the normal poorly tumorigenic transformed prostate epithelium and that this pathway is disrupted in the aggressive, metastatic PCa. In our previous studies AR expression in PC3 cells led to G1 cell cycle arrest and senescence. Despite its effect on cell proliferation, miR-200b failed to cause growth arrest or senescence in vitro and in vivo (data not shown) suggesting that ARinduced senescence occurs independently of miR-200b. Interestingly, in the study by He et al., decreased miR-200b occurred in the cells with perturbed AR signaling (PC-3 and androgenindependent sub-clone of LNCaP; however, this study established a causative link between miR-200b expression and p73 (see above) but not AR [31] .
The role of the miR-200 family in the suppression of mesenchymal characteristics and metastasis is firmly established in kidney, gastric, and breast cancers [11] . Similarly, the loss of miR-200 is associated with EMT of the PCa. In murine adenocarcinoma of the prostate there is a direct self-reinforcing regulatory loop where miR-1 and miR-200 are decreased in the course of progression causing de-repression of Slug (SNAI2), which in turn blocks miR-1 and miR-200 transcription and amplifies EMT [42] . In addition, the exposure to exogenous PDGF-B as well as its stable overexpression dramatically augments the EMT features in cultured PC-3 PCa cells. In this case, the enhanced mesenchymal features are associated with a decrease of miR-200b and re-introduction of miR-200b significantly inhibits the migration and invasion due to PDGF-B [35] . In agreement with these findings, miR-200b increased epithelial features of the PC-3 cells and reduced some of the mesenchymal markers, such as vimentin and fibronectin. The expression levels of CK8 and CK18, the markers of AR-positive, fully differentiated prostatic epithelium [43, 44] , were much higher in the presence of miR200b.
In agreement, we found the partial reversal of the EMT signature upon miR-200b expression, with increased E-cadherin and decreased Fibronectin, Vimentin, and ZEB1. These changes could be more dramatic if multiple miR-200 family members were activated, however even a single member, miR-200b, caused a dramatic reduction in the invasive potential of the PC-3 cells and a striking decrease in spontaneous regional metastasis in an orthotopic model. We were unable to demonstrate the change in SNAI2, which may reflect the difference in the target spectrum between the murine and human cells.
The effect of miR-200 family on angiogenesis has been established only recently. One study implicates miR-200c in the regulation of angiogenesis in the endometrial tissue, by suppressing vascular endothelial growth factor (VEGF) and its VEGF receptor 2 (FLT1) [45] . Another very recent analysis elucidates the link between increased angiogenesis in the breast, ovarian and renal cancers and the loss of miR-200a and b, whereby miR-200a/b collectively block the expression of interleukin-8 (IL-8) and CXCL1, a small cytokine previously called GRO1 [46] . The IL-8 contributes the angiogenesis proper (the sprouting of preexisting capillaries), while CXCL1 supports the recruitment of the bone marrow-derived progenitor cells to the tumor neovasculature. In agreement we observe a marked decrease in angiogenesis in prostate cancer xenografts upon miR-200b overexpression. This decreased angiogenesis is likely to further attenuate metastatic burden in a model where PC-3 cells metastasize spontaneously from an orthotopic site.
In conclusion, we identified miR-200b as a factor in decreased tumor growth when expressed in PC3 cells. We also found evidence that miR-200b could reverse or hinder EMT as described in other cell lines and for the first time demonstrated the anti-metastatic activity of miR-200 in an orthotopic preclinical model of PCa that recapitulates PCa progression in an appropriate microenvironment, which includes microvasculature. The inclusion of other members of the miR-200 family may shed further light on their role in PCa proliferation and survival and provide compelling rationale for miR-200 based treatment for the metastatic PCa. Figure S1 (PDF) Figure S2 (PDF) Table S1
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